Sainz, L.; Riera, P.; Moya, P.; Bernal, S.; Casademont, J.; DÃaz-Torné, C.; Millán, A.M.; Park, H.S.; Lasa, A.; Corominas, H.
Role of IL6R Genetic Variants in Predicting Response to Tocilizumab in Patients with Rheumatoid Arthritis. Pharmaceutics 2022, 14, 1942.
https://doi.org/10.3390/pharmaceutics14091942
AMA Style
Sainz L, Riera P, Moya P, Bernal S, Casademont J, DÃaz-Torné C, Millán AM, Park HS, Lasa A, Corominas H.
Role of IL6R Genetic Variants in Predicting Response to Tocilizumab in Patients with Rheumatoid Arthritis. Pharmaceutics. 2022; 14(9):1942.
https://doi.org/10.3390/pharmaceutics14091942
Chicago/Turabian Style
Sainz, Luis, Pau Riera, Patricia Moya, Sara Bernal, Jordi Casademont, Cesar DÃaz-Torné, Ana Milena Millán, Hye Sang Park, Adriana Lasa, and Héctor Corominas.
2022. "Role of IL6R Genetic Variants in Predicting Response to Tocilizumab in Patients with Rheumatoid Arthritis" Pharmaceutics 14, no. 9: 1942.
https://doi.org/10.3390/pharmaceutics14091942
APA Style
Sainz, L., Riera, P., Moya, P., Bernal, S., Casademont, J., DÃaz-Torné, C., Millán, A. M., Park, H. S., Lasa, A., & Corominas, H.
(2022). Role of IL6R Genetic Variants in Predicting Response to Tocilizumab in Patients with Rheumatoid Arthritis. Pharmaceutics, 14(9), 1942.
https://doi.org/10.3390/pharmaceutics14091942
